Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

The French drugmaker added the BTK inhibitor tolebrutinib to its pipeline by acquiring Principia for $3.7 billion. Facing down skepticism, Sanofi guided the asset to mixed phase 3 data last year ...

Tolebrutinib has been submitted in line with ... This is a demonstration of Sanofi's commitment, unwavering commitment to patients with MS. Thanks very much. I'll just, go simple and try to ...

Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.

Sanofi also has a strong immunology and neuro-inflammation pipeline, which includes some potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.